Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenvatinib, and Tislelizumab-designed to induce significant regression of both the tumor burden and the PVTT. The primary objective is to determine the Technical Resectability Rate (TRR), assessing the potential for this triple-combination therapy to downstage initially unresectable disease to a state suitable for curative-intent R0 surgical resection.

NCT Number	NCT07483359
Lead Sponsor	First Hospital of China Medical University Collaborators: Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Yanbian University
Conditions	Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
Enrollment	38 participants
Start Date	2026-05-20
Primary Completion	2027-06 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-28